Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 3/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sabcomeline SCHEMBL3133975 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL3838658 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL3133982 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL7076525 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL7079710 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL6392265 | 0.98 | CHRM2 (0.97) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL34463221 | 0.98 | CHRM2 (0.97) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL18049048 | 0.98 | CHRM2 (0.97) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL6629873 | 0.98 | CHRM2 (0.97) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL6629868 | 0.98 | CHRM2 (0.97) | CHRM2CHRM4CHRM1CHRM3CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0392803-B1 | Novel compounds | BEECHAM GROUP PLC (GB) | 2004-06-16 | — | — | EP | claimed |
| EP-0871445-A4 | COMPOSITION FOR TREATING PAIN | LILLY CO ELI (US) | 2001-01-10 | — | — | EP | claimed |
| JP-2000501709-A | — | — | 2000-02-15 | — | — | JP | claimed |
| EP-0871445-A1 | COMPOSITION FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1998-10-21 | — | — | EP | claimed |
| US-RE35593-E | THERAPY FOR DERMENTIA | BEECHAM GROUP P.L.C. | 1997-08-19 | — | — | US | claimed |
| WO-1997020561-A1 | COMPOSITION FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1997-06-12 | — | — | WO | claimed |
| EP-0392803-A1 | Novel compounds | Beecham Group p.l.c. (GB) | 1990-10-17 | — | — | EP | claimed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20090318414-A1 | Mono and Combination Therapy with M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Prodromal Syndrome | MINSTER RESEARCH LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090306040-A1 | Mono and Combination Therapy of M1/M4 Agonist (Sabcomeline) for Treatment of Negative Symptoms of Schizophrenia | MINSTER RESEARCH LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| US-20090281078-A1 | COMBINATION OF SABCOMELINE WITH A NEUROLEPTIC AGENT TO TREAT PSYCHOTIC DISORDERS | MINSTER RESEARCH LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090258084-A1 | Mono and Combination Therapy with a M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Cognitive Disorders in Schizophrenia | MINSTER RESEARCH LIMITED (GB) | 2009-10-15 | — | — | US | disclosed |
| EP-0626961-B1 | PROCESS FOR THE PREPARATION OF CYANO-METHOXYIMINOMETHYL DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2000-07-05 | — | — | EP | disclosed |
| EP-0984008-A2 | Nitrosation process | SMITHKLINE BEECHAM PLC (GB) | 2000-03-08 | — | — | EP | disclosed |
| US-RE35593-E | THERAPY FOR DERMENTIA | BEECHAM GROUP P.L.C. | 1997-08-19 | — | — | US | disclosed |
| US-5545740-A | Nitrosation process | SMITHKLINE BEECHAM, P.L.C. (GB) | 1996-08-13 | — | — | US | disclosed |
| EP-0626961-A1 | NITROSATION PROCESS | SMITHKLINE BEECHAM PLC (GB) | 1994-12-07 | — | — | EP | disclosed |
| US-5278170-A | Azabicylo oxime compounds | BEECHAM GROUP P.L.C. (GB) | 1994-01-11 | — | — | US | disclosed |
| WO-1993017018-A1 | NITROSATION PROCESS | SMITHKLINE BEECHAM PLC (GB) | 1993-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | CHRM2 15/4885CHRM4 17/4885CHRM1 24/4885 |
| US-20090281078-A1 | COMBINATION OF SABCOMELINE WITH A NEUROLEPTIC AGENT TO TREAT PSYCHOTIC DISORDERS | SLC6A3, SLC6A2, BDNF | CHRM2 1719/4885CHRM4 1401/4885CHRM1 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.